The Autoimmune Association of South Africa (AASA) calls for the Council for Medical Schemes (CMS) to issue clear guidance on medical schemes’ obligations to cover costly specialised treatments for autoimmune diseases amidst growing patient disputes.

Membership Required

You must be a member to access this content.

View Membership Levels

Already a member? Log in here